Company news

Vistagen Therapeutics, Inc. news in 2022

Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder

December 29, 2022

Vistagen to Acquire Pherin Pharmaceuticals

December 20, 2022

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder

December 5, 2022

Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder

November 29, 2022

Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

November 16, 2022

Vistagen Reports Second Quarter Financial Results and Provides Corporate Update

November 9, 2022

Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022

November 3, 2022

Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022

October 18, 2022

Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary

October 5, 2022

Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis

September 7, 2022

VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

August 10, 2022

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

July 21, 2022

VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update

June 22, 2022

VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder

June 21, 2022

VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022

June 16, 2022

VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting

June 1, 2022

VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder

May 4, 2022

VistaGen Appoints Reid Adler as Chief Legal Officer

May 1, 2022

VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B

April 11, 2022

VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

February 9, 2022

Calls in 2022

Decks in 2022